Nanotherapies are emerging rapidly as options to treat cardiovascular disease. However, insufficient and heterogeneous delivery remain critical issues. Novel strategies to boost targeted delivery of systemically administered nanoparticles by optimizing the particle physical properties or using immune cells as carriers promise to increase nanotherapeutic effectiveness in cardiovascular and other inflammatory diseases.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fish, M. B. et al. Deformable microparticles for shuttling nanoparticles to the vascular wall. Sci. Adv. 7, eabe0143 (2021).
Huang, S. S. et al. Immune cell shuttle for precise delivery of nanotherapeutics for heart disease and cancer. Sci. Adv. 7, eabf2400 (2021).
Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).
Kanthi, Y., de la Zerda, A. & Smith, B. R. Nanotherapeutic shots through the heart of plaque. ACS Nano 14, 1236–1242 (2020).
Smith, B. R. & Gambhir, S. S. Nanomaterials for in vivo imaging. Chem. Rev. 117, 901–986 (2017).
Smith, B. R. et al. Real-time intravital imaging of RGD-quantum dot binding to luminal endothelium in mouse tumor neovasculature. Nano Lett. 8, 2599–2606 (2008).
Namdee, K., Thompson, A. J., Charoenphol, P. & Eniola-Adefeso, O. Margination propensity of vascular-targeted spheres from blood flow in a microfluidic model of human microvessels. Langmuir 29, 2530–2535 (2013).
Smith, B. R. et al. Selective uptake of single walled carbon nanotubes by circulating monocytes for enhanced tumour delivery. Nat. Nanotechnol. 9, 481–487 (2014).
Sofias, A. M. et al. Cyclic arginine–glycine–aspartate-decorated lipid nanoparticle targeting toward inflammatory lesions involves hitchhiking with phagocytes. Adv. Sci. 8, 2100370 (2021).
Flores, A. M. et al. Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis. Nat. Nanotechnol. 15, 154–161 (2020).
Acknowledgements
The author is grateful to the funding agencies AHA Transformational Project Award 18TPA34230113 and NIH grant R01 CA244491, and to Y. Zhang (MSU, USA) for initial figure preparation and A. Alessio for discussion (MSU, USA).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Smith, B.R. Nanotherapeutics for cardiovascular disease. Nat Rev Cardiol 18, 617–618 (2021). https://doi.org/10.1038/s41569-021-00594-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-021-00594-5